KF
CRSP icon

Krilogy Financial’s CRISPR Therapeutics CRSP Stock Holding History

Krilogy Financial’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-20,872
Closed -$1.13M – 217
2024
Q2 		$1.13M Buy
20,872
+10,050
+93% +$581K 0.08% 154
2024
Q1 		$738K Sell
10,822
-4,872
-31% -$349K 0.06% 178
2023
Q4 		$982K Buy
+15,694
New +$868K 0.08% 148
2018
Q2 		– Sell
-200
Closed -$9K – 255
2018
Q1 		$9K Sell
200
-100
-33% -$4.13K ﹤0.01% 538
2017
Q4 		$7K Hold
300
– – ﹤0.01% 556
2017
Q3 		$5K Hold
300
– – ﹤0.01% 644
2017
Q2 		$5K Buy
+300
New +$4.96K ﹤0.01% 588

Other funds holding CRSP

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Krilogy Financial's CRSP Position: Q3 2024 in Review

Krilogy Financial sold out of CRISPR Therapeutics (CRSP) in Q3 2024, closing a stake of 20,872 shares — an estimated $1.13M sold.

Krilogy Financial first reported a position in CRSP in Q2 2017 and held it in 7 quarters. The position peaked at $1.13M in Q2 2024. 416 funds tracked by Wall St. Rank hold CRSP as of Q3 2024.

  • Krilogy Financial reported no remaining CRISPR Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Krilogy Financial sold 20,872 CRISPR Therapeutics shares in Q3 2024, an estimated $1.13M.
  • Krilogy Financial first reported a position in CRISPR Therapeutics in Q2 2017 and held it in 7 quarters.
  • Krilogy Financial's CRISPR Therapeutics position peaked at $1.13M in Q2 2024.
  • 416 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2024.

Based on Krilogy Financial's 13F filing for Q3 2024, filed 15 Oct 2024.